|
NovImmune raised CHF 15 million (EUR 10M) in May 2000 and CHF 10,8 million (Euros 7.2) in equity and CHF 12 million (EUR 8) in milestones in April 2005. Its main investors are:
- Novartis Venture Fund
- Serono
- Lombard Odier Immunology Fund
- Aventic Partners AG
- Genevest Consulting Group
- Swiss Partners Investment Network
Inquiry concerning possible investments, please contact:
Jack Barbut, CEO
Tel. +41 22 839 71 41
Fax +41 22 593 5105
jbarbut@novimmune.com
|
